No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
HK Stock MarketDetailed Quotes
02196 FOSUN PHARMA
- 13.240
- +0.200+1.53%
Not Open Jun 19 16:08 CST
35.38BMarket Cap15.88P/E (TTM)
13.300High13.040Low2.27MVolume13.160Open13.040Pre Close29.90MTurnover0.41%Turnover Ratio13.37P/E (Static)2.67BShares21.14052wk High0.69P/B7.31BFloat Cap11.32052wk Low0.46Dividend TTM551.94MShs Float80.880Historical High0.460Dividend LFY1.99%Amplitude6.197Historical Low13.180Avg Price500Lot Size3.47%Div YieldTTM3.47%Div Yield LFY
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Fosun Pharma (600196.SH): plans to sell 6.01% equity of its subsidiary Gland Pharma Limited.
On June 19th, Gelunhui reported that Fosun Pharma (600196.SH) announced that on June 19th, 2024 Indian time, its wholly-owned subsidiary Fosun Pharma Singapore sold a total of 9,900,000 shares of Gland Pharma (about 6.01% of the total number of Gland Pharma shares as of June 19, 2024, which is 164,751,723 shares), at an average price of 1,771.81 Indian rupees/share (pre-tax), with a total transaction value of 17.541 billion Indian rupees (pre-tax), equivalent to approximately 2.11.
Express News | Shanghai Fosun Pharma Says Unit Sells 6.0% Stake in Gland Pharma for About $211 Mln
Fosun Pharma (02196): Chen Bing was elected as the Chairman of the Supervisory Board.
Fosun Pharma (02196) announced that Ren Qian has resigned from the positions of employee supervisor and chairman of the board of supervisors. Wang Lina has been appointed as an employee...
Express News | Fosun Is Said to Plan Block Deals to Pare 6% Stake in Gland Pharma - Bloomberg News
Fosun Pharma (02196) intends to guarantee the debt under the financing of no more than 300 million yuan applied by Fosun Pharma Industry.
Fosun Pharma (02196) announced that the company plans to apply for the principal of Bank of China on behalf of its subsidiary, Fosun Pharma Industry.
Private Companies Own 36% of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) Shares but Retail Investors Control 49% of the Company
Key Insights The considerable ownership by retail investors in Shanghai Fosun Pharmaceutical (Group) indicates that they collectively have a greater say in management and business strategy The top 2
Comments
$Hang Seng Index(800000.HK$ concluded the day at 19,617, down 342 pts or 1.7%. $Hang Seng China Enterprises Index(800100.HK$ sagged 131 pts or 2% to 6,601. $Hang Seng TECH Index(800700.HK$ faded 137 pts or 3.5% to 3,824. The turnover aggregated $106.657 billion.
Techs slid as the market continued to be watchful of the Sino-US relations:
$BABA-SW(09988.HK$ dived 3.2% to $84.1.
$TENCENT(00700.HK$ sank 1.9% to $338.4.
$MEITUAN-W(03690.HK$ , $XIAOMI-W(01810.HK$ , ...
Techs slid as the market continued to be watchful of the Sino-US relations:
$BABA-SW(09988.HK$ dived 3.2% to $84.1.
$TENCENT(00700.HK$ sank 1.9% to $338.4.
$MEITUAN-W(03690.HK$ , $XIAOMI-W(01810.HK$ , ...
1
Core point
1. In the past three years, China's medical beauty industry has undergone earth-shaking changes, and non-surgical products occupy the mainstream
2. The brand is a marketing tool and a social contract for the legal entity to face society. Last year, it began to issue documents on supervising medical aesthetics, focusing on doctors' qualifications, marketing, and the capabilities of three types of ...
1. In the past three years, China's medical beauty industry has undergone earth-shaking changes, and non-surgical products occupy the mainstream
2. The brand is a marketing tool and a social contract for the legal entity to face society. Last year, it began to issue documents on supervising medical aesthetics, focusing on doctors' qualifications, marketing, and the capabilities of three types of ...
The domestic COVID-19 oral drug Azifodine is planned to be sold online, and $FOSUN PHARMA(02196.HK$ shares were opened 12% higher to 29 yuan.
$Pfizer(PFE.US$ $AIM VACCINE(06660.HK$
$Pfizer(PFE.US$ $AIM VACCINE(06660.HK$
7
2
https://alphaedgeinvesting.com/2022/06/02/bllomberg-chinese-mrna-shot-beat-sinovac-as-booster-but-caused-more-fevers/
$Sinovac Biotech(SVA.US$ $FOSUN PHARMA(02196.HK$ $Shanghai Fosun Pharmaceutical(600196.SH$ $CanSino Biologics Inc.(688185.SH$ $CANSINOBIO(06185.HK$ $Walvax Biotechnology(300142.SZ$ $Chongqing Zhifei Biological Products(300122.SZ$
$Sinovac Biotech(SVA.US$ $FOSUN PHARMA(02196.HK$ $Shanghai Fosun Pharmaceutical(600196.SH$ $CanSino Biologics Inc.(688185.SH$ $CANSINOBIO(06185.HK$ $Walvax Biotechnology(300142.SZ$ $Chongqing Zhifei Biological Products(300122.SZ$
Read more
Analysis
Price Target
No Data
Heat List
HK
Overall
Symbol
Latest Price
%Chg